单位：[1]Department of Pathology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning, 110001, China中国医科大学附属盛京医院[2]Department of Medical Oncology, First Hospital of China Medical University, Shenyang, Liaoning, 110001, China[3]Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China[4]Graduate School of Peking Union Medical College, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, 100029, China[5]Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310016, China[6]Department of Medical Oncology, Fourth People's Hospital of Shenyang, Shenyang, Liaoning, 110001, China[7]First Laboratory of The Cancer Institute, First Hospital of China Medical University, 155 North Nanjing Street, Shenyang, Liaoning, 110001, China
Paclitaxel is one of the most effective chemotherapy drugs for breast cancer worldwide but 20-30% patients show primary resistance to the drug. Screening and identification of markers that facilitate effective and rapid prediction of sensitivity to paclitaxel is therefore an urgent medical requirement. In the present study, G protein signaling modulator 2 (GPSM2) mRNA levels were significantly associated with taxane sensitivity in experiments based on the Gene Expression Omnibus (GEO) online database. Immunohistochemical analysis consistently revealed a significant association of GPSM2 protein levels with paclitaxel sensitivity in breast cancer patients. Knockdown of GPSM2 reduced the sensitivity of breast cancer cells to paclitaxel via regulation of the cell cycle. Animal experiments further corroborated our in vitro findings. These results suggest that GPSM2 plays an important role in breast cancer resistance, supporting its utility as a potential target for improving drug susceptibility in patients as well as a marker of paclitaxel sensitivity.
基金：
Shenyang Special Funds of Technology Innovation Plan Projects [F14-231-1-46]; Liaoning Science and Technology Plan Projects [2013225021]; Liaoning Natural Science Foundation of 2018 [20180530050]
第一作者单位：[1]Department of Pathology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning, 110001, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pathology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning, 110001, China[7]First Laboratory of The Cancer Institute, First Hospital of China Medical University, 155 North Nanjing Street, Shenyang, Liaoning, 110001, China[*1]Department of Pathology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping, Shenyang, Liaoning 110001, P.R. China[*2]The First Laboratory of the Cancer Institute,The First Hospital of China Medical University, 155 North Nanjing Street, Shenyang, Liaoning 110001, P.R. China
推荐引用方式(GB/T 7714)：
ZHE ZHANG,ZHI LI,MINGMING DENG,et al.Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer[J].ONCOLOGY REPORTS.2020,43(3):965-974.doi:10.3892/or.2020.7471.
APA：
ZHE ZHANG,ZHI LI,MINGMING DENG,BOFANG LIU,XING XIN...&QINGJIE LV.(2020).Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer.ONCOLOGY REPORTS,43,(3)
MLA：
ZHE ZHANG,et al."Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer".ONCOLOGY REPORTS 43..3(2020):965-974
